Head-To-Head Analysis: Biotricity (NASDAQ:BTCY) and Bioventus (NYSE:BVS)

Biotricity (NASDAQ:BTCY) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Volatility and Risk

Biotricity has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Earnings and Valuation

This table compares Biotricity and Bioventus”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	0.68	-$14.09 million	($0.17)	-1.72
Bioventus	$563.83 million	1.16	-$156.23 million	$0.12	65.75

Biotricity has higher earnings, but lower revenue than Bioventus. Biotricity is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 33.0% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Biotricity and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Bioventus	-7.11%	15.61%	4.01%

Analyst Ratings

This is a breakdown of recent ratings for Biotricity and Bioventus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	0	0	0	0.00
Bioventus	0	0	3	0	3.00

Bioventus has a consensus price target of $14.00, suggesting a potential upside of 77.44%. Given Bioventus’ stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than Biotricity.

Summary

Bioventus beats Biotricity on 11 of the 14 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.